Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment


> on Spotify
> on Apple podcasts
> on Amazon Music

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation. They offer expert insights on how digital pathology and artificial intelligence are making it much easier to accurately measure HER2 levels, meaning patients can get the most effective ADC treatments for their cancer.

Host

⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpace

Guests

⁠Dr. Rob Monroe⁠, Vice President and Chief Scientific Officer, Oncology, Danaher Corporation; Chief Medical Officer, Leica Biosystems

⁠Jennifer Faikish⁠, Vice President and Franchise Head, Oncology, Danaher Corporation

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.



Content Curated Originally From Here